|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Röcken C: Molecular classification of
gastric cancer. Expert Rev Mol Diagn. 17:293–301. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Correa P: A human model of gastric
carcinogenesis. Cancer Res. 48:3554–3560. 1988.PubMed/NCBI
|
|
4
|
Amieva M and Peek RM Jr: Pathobiology of
Helicobacter pylori-Induced Gastric Cancer.
Gastroenterology. 150:64–78. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cavatorta O, Scida S, Miraglia C, Barchi
A, Nouvenne A, Leandro G, Meschi T, De' Angelis GL and Di Mario F:
Epidemiology of gastric cancer and risk factors. Acta Biomed.
89:82–87. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Melchiades JL, Zabaglia LM, Sallas ML,
Orcini WA, Chen E, Smith MAC, Payão SLM and Rasmussen LT:
Polymorphisms and haplotypes of the interleukin 2 gene are
associated with an increased risk of gastric cancer. The possible
involvement of Helicobacter pylori. Cytokine. 96:203–207.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Busuttil RA, Zapparoli GV, Haupt S,
Fennell C, Wong SQ, Pang JM, Takeno EA, Mitchell C, Di Costanzo N,
Fox S, et al: Role of p53 in the progression of gastric cancer.
Oncotarget. 5:12016–12026. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Aubrey BJ, Strasser A and Kelly GL:
Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb
Perspect Med. 6(a026062)2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yu H, Huang YJ, Liu Z, Wang LE, Li G,
Sturgis EM, Johnson DG and Wei Q: Effects of MDM2 promoter
polymorphisms and p53 codon 72 polymorphism on risk and age at
onset of squamous cell carcinoma of the head and neck. Mol
Carcinog. 50:697–706. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Baliou E, Nonni A, Keramopoulos D, Ragos
V, Tsiambas E, Patsouris E and Pavlakis K: Deregulation of p53-MDM2
auto-regulatory pathway in breast carcinoma. J BUON. 21:1099–1103.
2016.PubMed/NCBI
|
|
11
|
Bond GL, Hu W and Levine AJ: MDM2 is a
central node in the p53 pathway: 12 years and counting. Curr Cancer
Drug Targets. 5:3–8. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Günther T, Schneider-Stock R, Häckel C,
Kasper HU, Pross M, Hackelsberger A, Lippert H and Roessner A: Mdm2
gene amplification in gastric cancer correlation with expression of
Mdm2 protein and p53 alterations. Mod Pathol. 13:621–626.
2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ooi A, Oyama T, Nakamura R, Tajiri R,
Ikeda H, Fushida S, Nakamura H and Dobashi Y: Semi-comprehensive
analysis of gene amplification in gastric cancers using multiplex
ligation-dependent probe amplification and fluorescence in situ
hybridization. Mod Pathol. 28:861–871. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Qin X, Peng Q, Tang W, Lao X, Chen Z, Lai
H, Deng Y, Mo C, Sui J, Wu J, et al: An updated meta-analysis on
the association of MDM2 SNP309 polymorphism with colorectal cancer
risk. PLoS One. 8(e76031)2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sousa H, Pando M, Breda E, Catarino R and
Medeiros R: Role of the MDM2 SNP309 polymorphism in the initiation
and early age of onset of nasopharyngeal carcinoma. Mol Carcinog.
50:73–79. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Varmazyar S, Marashi SM, Shoja Z,
Tornesello ML, Buonaguro FM, Shahmahmoodi S, Safaie-Naraghi Z and
Jalilvand S: MDM2 gene polymorphisms and risk of classic Kaposi's
sarcoma among Iranian patients. Med Microbiol Immunol (Berl).
206:157–163. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Grochola LF, Zeron-Medina J, Mériaux S and
Bond GL: Single-nucleotide polymorphisms in the p53 signaling
pathway. Cold Spring Harb Perspect Biol. 2(a001032)2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gansmo LB, Vatten L, Romundstad P, Hveem
K, Ryan BM, Harris CC, Knappskog S and Lønning PE: Associations
between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and
incidence of cancer of the breast, lung, colon and prostate.
Oncotarget. 7:28637–28646. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nag S, Qin J, Srivenugopal KS, Wang M and
Zhang R: The MDM2-p53 pathway revisited. J Biomed Res. 27:254–271.
2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mendoza M, Mandani G and Momand J: The
MDM2 gene family. Biomol Concepts. 5:9–19. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Elingarami S, Liu H, Kalinjuma AV, Hu W,
Li S and He N: Polymorphisms in NEIL-2, APE-1, CYP2E1 and MDM2
genes are independent predictors of gastric cancer risk in a
Northern Jiangsu population (China). J Nanosci Nanotechnol.
15:4815–4828. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Moradi MT, Salehi Z, Aminian K and
Yazdanbod A: Effects of p53 codon 72 and MDM2 SNP309 polymorphisms
on gastric cancer risk among the Iranian population. Asian Pac J
Cancer Prev. 15:7413–7417. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ohmiya N, Taguchi A, Mabuchi N, Itoh A,
Hirooka Y, Niwa Y and Goto H: MDM2 promoter polymorphism is
associated with both an increased susceptibility to gastric
carcinoma and poor prognosis. J Clin Oncol. 24:4434–4440.
2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Page MJ, Moher D, Bossuyt PM, Boutron I,
Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: PRISMA 2020 explanation and elaboration: Updated
guidance and exemplars for reporting systematic reviews. BMJ.
372(n160)2021.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Wells GA, Shea B, O'Connell D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for Assessing the Quality of Nonrandomised Studies in
Meta-Analyses. Ottawa Health Research Institute, Ottawa, Ontario,
1999.
|
|
26
|
Chen B, Wang J, Chen Y, Gu X and Feng X:
The MDM2 rs937283 A > G variant significantly increases the risk
of lung and gastric cancer in Chinese population. Int J Clin Oncol.
23:867–876. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cavalcante GC, Amador MA, Ribeiro Dos
Santos AM, Carvalho DC, Andrade RB, Pereira EE, Fernandes MR, Costa
DF, Santos NP, Assumpção PP, et al: Analysis of 12 variants in the
development of gastric and colorectal cancers. World J
Gastroenterol. 23:8533–8543. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tas A, Atabey M, Caglayan G, Bostanci ME,
Sahin Bolukbasi S, Topcu O and Silig Y: Investigation of the
association between the MDM2 T309G polymorphism and gastric cancer.
Biomed Rep. 7:469–473. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Moradi MT, Salehi Z, Asl SF, Aminian K and
Hashtchin AR: Helicobacter pylori infection and MDM2 SNP309
association with gastric cancer susceptibility. Genet Test Mol
Biomarkers. 17:794–798. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pan X, Li Y, Feng J, Wang X, Hao B, Shi R
and Zhang G: A functional polymorphism T309G in MDM2 gene promoter,
intensified by Helicobacter pylori lipopolysaccharide, is
associated with both an increased susceptibility and poor prognosis
of gastric carcinoma in Chinese patients. BMC Cancer.
13(126)2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wu GC and Zhang ZT: Genetic association of
single nucleotide polymorphisms in P53 pathway with gastric cancer
risk in a Chinese Han population. Med Oncol. 32(401)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang X, Yang J, Ho B, Yang Y, Huang Z,
Zhang Z and Zhang G: Interaction of Helicobacter pylori with
genetic variants in the MDM2 promoter, is associated with gastric
cancer susceptibility in Chinese patients. Helicobacter.
14:114–119. 2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Cho YG, Choi BJ, Song JH, Kim CJ, Cao Z,
Nam SW, Lee JY and Park WS: No association of MDM2 T309G
polymorphism with susceptibility to Korean gastric cancer patients.
Neoplasma. 55:256–260. 2008.PubMed/NCBI
|
|
34
|
Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun
T, Zhao D, Yu D, Liu J and Lin D: Interaction of P53 Arg72Pro and
MDM2 T309G polymorphisms and their associations with risk of
gastric cardia cancer. Carcinogenesis. 28:1996–2001.
2007.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Horita N and Kaneko T: Genetic model
selection for a case-control study and a meta-analysis. Meta Gene.
5:1–8. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kasper HU, Schneider-Stock R, Mellin W,
Günther T and Roessner A: P53-protein accumulation and MDM2-protein
overexpression in gastric carcinomas. No apparent correlation with
survival. Pathol Res Pract. 195:815–820. 1999.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Aboushousha T, Helal N, Hammam O, Ibrahim
M, Khaled S, Mostafa A and Anas A: Overview of MDM2 and B-RAF
Expression in Gastric Lesions. Open Access Maced J Med Sci.
6:1795–1802. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jiao Y, Jiang Z, Wu Y, Chen X, Xiao X and
Yu H: A Functional Polymorphism (rs937283) in the MDM2 Promoter
Region is Associated with Poor Prognosis of Retinoblastoma in
Chinese Han Population. Sci Rep. 6(31240)2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chen B, Wang J, Wang J, Zhang J, Gu X and
Feng X: The Study of MDM2 rs937283 Variant and Cancer
Susceptibility in a Central Chinese Population. Technol Cancer Res
Treat. 17(1533033818801550)2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Cao Q, Wang Y, Song X and Yang W:
Association between MDM2 rs2279744, MDM2 rs937283, and p21
rs1801270 polymorphisms and retinoblastoma susceptibility. Medicine
(Baltimore). 97(e13547)2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Gallegos-Arreola MP, Márquez-Rosales MG,
Sánchez-Corona J, Figuera LE, Zúñiga-González G, Puebla-Pérez AM,
Delgado-Saucedo JI and Montoya-Fuentes H: Association of the
Del1518 Promoter (rs3730485) Polymorphism in the MDM2 Gene with
Breast Cancer in a Mexican Population. Ann Clin Lab Sci.
47:291–297. 2017.PubMed/NCBI
|
|
42
|
Hashemi M, Amininia S, Ebrahimi M,
Simforoosh N, Basiri A, Ziaee SAM, Narouie B, Sotoudeh M,
Mollakouchekian MJ, Rezghi Maleki E, et al: Association between
polymorphisms in TP53 and MDM2 genes and susceptibility to prostate
cancer. Oncol Lett. 13:2483–2489. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Gansmo LB, Bjørnslett M, Halle MK,
Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE
and Knappskog S: MDM2 promoter polymorphism del1518 (rs3730485) and
its impact on endometrial and ovarian cancer risk. BMC Cancer.
17(97)2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Dong D, Gao X, Zhu Z, Yu Q, Bian S and Gao
Y: A 40-bp insertion/deletion polymorphism in the constitutive
promoter of MDM2 confers risk for hepatocellular carcinoma in a
Chinese population. Gene. 497:66–70. 2012.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wan Y, Wu W, Yin Z, Guan P and Zhou B:
MDM2 SNP309, gene-gene interaction, and tumor susceptibility: An
updated meta-analysis. BMC Cancer. 11(208)2011.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Avirmed S, Wang BS, Selenge B, Sanjaajamts
A, Ganbat B, Erdenebileg U, Purevsuren M, Jigjidsuren S, Batmunkh M
and Lee YJ: Association between MDM2-SNP309 and p53R72P
polymorphisms and the risk of bladder cancer in the Mongolian
population. Mol Clin Oncol. 7:412–420. 2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zou X, Zhang Y, Zhang L, Li J, Zhu C,
Cheng Q, Zhou J and Chen Y: Association between MDM2 SNP309 and
endometrial cancer risk: A PRISMA-compliant meta-analysis. Medicine
(Baltimore). 97(e13273)2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Knappskog S and Lønning PE: MDM2 SNP309
and risk of cervical cancer. Tumour Biol. 35:6185–6186.
2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Wang W, Du M, Gu D, Zhu L, Chu H, Tong N,
Zhang Z, Xu Z and Wang M: MDM2 SNP309 polymorphism is associated
with colorectal cancer risk. Sci Rep. 4(4851)2014.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Shen W, Hu P, Cao JQ, Liu XX and Shao JH:
MDM2 oncogene, E3 ubiquitin protein ligase T309G polymorphism and
risk of oesophageal or gastric cancer: Meta-analysis of 15 studies.
J Int Med Res. 42:1065–1076. 2014.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Chen W, Wu Q and Ren H: Meta-analysis of
associations between MDM2 SNP309 polymorphism and gastric cancer
risk. Biomed Rep. 2:105–111. 2014.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Song B, Duan ZY, Zhong YH, Lei N, Yang YQ
and Luo KY: Meta-analysis of the MDM2 T309G polymorphism and
gastric cancer risk. Asian Pac J Cancer Prev. 14:6649–6651.
2014.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Ma Y, Bian J and Cao H: MDM2 SNP309
rs2279744 polymorphism and gastric cancer risk: A meta-analysis.
PLoS One. 8(e56918)2013.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Tian X, Tian Y, Ma P, Sui CG, Meng FD, Li
Y, Fu LY, Jiang T, Wang Y, Ji FJ, et al: Association between MDM2
SNP309 T>G and risk of gastric cancer: A meta-analysis. Asian
Pac J Cancer Prev. 14:1925–1929. 2013.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Chen B, Cao L, Hu KW, Zhang JW, Meng XL
and Xiong MM: MDM2 SNP309 is an ethnicity-dependent risk factor for
digestive tract cancers. Tumour Biol. 35:3431–3438. 2014.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Ohnstad HO, Castro R, Sun J, Heintz KM,
Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA and Myklebost
O: Correlation of TP53 and MDM2 genotypes with response to therapy
in sarcoma. Cancer. 119:1013–1022. 2013.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Tisato V, Voltan R, Gonelli A, Secchiero P
and Zauli G: MDM2/X inhibitors under clinical evaluation:
Perspectives for the management of hematological malignancies and
pediatric cancer. J Hematol Oncol. 10(133)2017.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Gupta A, Shah K, Oza MJ and Behl T:
Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for
cancer treatment. Biomed Pharmacother. 109:484–492. 2019.PubMed/NCBI View Article : Google Scholar
|
